Merck Licenses Polyplus Transfection Reagent | GenomeWeb

France's Polyplus Transfection announced this week that it has signed a deal to provide its proprietary polyethylenimine, or PEI, transfection reagents to Merck.

Under the deal, Merck acquired the rights to the prior use of PEI for transfection, and Polyplus will supply the drug maker with batches of linear PEI transfection reagent to its sites worldwide.

Financial terms of the arrangement were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.